Active, not recruitingPhase 3NCT03424018

An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

Studying Achondroplasia

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: BioMarin Pharmaceutical
Intervention: BMN 111(drug)
Enrollment: 119 enrolled
Eligibility: 6 years · All sexes
Timeline: 2017 – 2031

Study locations (24)

Children's Hospital & Research Center Oakland, Oakland, California, United States
Harbor - UCLA Medical Center, Torrance, California, United States
Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
Emory University, Atlanta, Georgia, United States
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Johns Hopkins University, Baltimore, Maryland, United States
University of Missouri, Columbia, Missouri, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Baylor College of Medicine, Houston, Texas, United States
Seattle Children's Hospital, Seattle, Washington, United States
Medical College of Wisconsin, Children's Hospital, Milwaukee, Wisconsin, United States
The Children's Hospital at Westmead, Westmead, New South Wales, Australia
Murdoch Children's Research Institute, Parkville, Victoria, Australia
Otto-von-Gericke Universitaet, Universitaetskinderklinik, Magdeburg, Germany
Universitätsklinikum Münster, Münster, Germany
+9 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03424018 on ClinicalTrials.gov

Other trials for Achondroplasia

Additional recruiting or active studies for the same condition.

See all trials for Achondroplasia →

← Back to all trials